Luteinizing-hormone Releasing Hormone Therapy and the Risk of Death From Alzheimer Disease

被引：24

作者：

D'Amico, Anthony V. ^{[1
,2
]}

Braccioforte, Michelle H. ^{[3
]}

Moran, Brian J. ^{[3
]}

Chen, Ming-Hui ^{[4
]}

机构：

[1] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02215 USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Prostate Canc Fdn Chicago, Dept Radiat Oncol, Westmont, IL USA

[4] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA

来源：

ALZHEIMER DISEASE & ASSOCIATED DISORDERS | 2010年 / 24卷 / 01期

关键词：

Alzheimer disease; hormone therapy; prostate cancer; PROSTATE-CANCER; COMPETING RISK; DEPOSITION; DEMENTIA;

D O I：

10.1097/WAD.0b013e31819cb8f4

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Purpose: We evaluated the risk of death from Alzheimer disease (AD) in men with prostate cancer undergoing treatment with or without a luteinizing-hormone releasing hormone (LHRH) agonist. Methods: Between 1997 and 2007, 6,647 men were treated with brachytherapy for prostate cancer with (N = 1,700) or without (N = 4,947) LHRH agonist therapy. Competing risks multivariable regression was performed to assess whether the use of a LHRH agonist was associated with the risk of death from AD adjusting for the presence of mild AD and age at presentation and known prostate cancer prognostic factors. Results: After a median follow-up of 4.1 years, 1.2% (81/6,647) of the study cohort died from AD accounting for 16% (81/506) of all observed mortality. There was a significant reduction in the risk of death from AD in men who were treated with a LHRH agonist for a median of 4.0 months as compared with those who were not [adjusted hazard ratio: 0.45 (95% confidence interval, 0.25-0.83); P = 0.01]. Conclusions: LHRH agonist use as compared with no use in men with prostate cancer was associated with a decreased risk of death from AD.

引用

页码：85 / 89

页数：5

共 26 条

[11] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].

D'Amico, AV ;

Whittington, R ;

Malkowicz, SB ;

Schultz, D ;

Blank, K ;

Broderick, GA ;

Tomaszewski, JE ;

Renshaw, AA ;

Kaplan, I ;

Beard, CJ ;

Wein, A .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974

[12] A proportional hazards model for the subdistribution of a competing risk [J].

Fine, JP ;

Gray, RJ .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509

[13] ON THE USE OF CAUSE-SPECIFIC FAILURE AND CONDITIONAL FAILURE PROBABILITIES - EXAMPLES FROM CLINICAL ONCOLOGY DATA [J].

GAYNOR, JJ ;

FEUER, EJ ;

TAN, CC ;

WU, DH ;

LITTLE, CR ;

STRAUS, DJ ;

CLARKSON, BD ;

BRENNAN, MF .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1993, 88 (422) :400-409

[14]

Gleason DF., 1977, UROLOGIC PATHOLOGY P, P171

[15] A CLASS OF K-SAMPLE TESTS FOR COMPARING THE CUMULATIVE INCIDENCE OF A COMPETING RISK [J].

GRAY, RJ .

ANNALS OF STATISTICS, 1988, 16 (03) :1141-1154

[16]

Klein JohnP., 2003, Survival analysis: techniques for censored and truncated data, P243

[17] The gonadotropin connection in Alzheimer's disease [J].

Meethal, SV ;

Smith, MA ;

Bowen, RL ;

Atwood, CS .

ENDOCRINE, 2005, 26 (03) :317-325

[18] Cognitive effects of hormone therapy in men with prostate cancer [J].

Nelson, Christian J. ;

Lee, Jennifer S. ;

Garnboa, Maria C. ;

Roth, Andrew J. .

CANCER, 2008, 113 (05) :1097-1106

[19] The cell cycle as a therapeutic target for Alzheimer's disease [J].

Neve, Rachael L. ;

McPhie, Donna L. .

PHARMACOLOGY & THERAPEUTICS, 2006, 111 (01) :99-113

[20] Involvement of oxidative stress in Alzheimer disease [J].

Nunomura, Akihiko ;

Castellani, Rudy J. ;

Zhu, Xiongwei ;

Moreira, Paula I. ;

Perry, George ;

Smith, Mark A. .

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2006, 65 (07) :631-641

← 1 2 3 →